Ascension Health will form a joint venture with a division of Envision Healthcare to provide an array of post-acute services, including home care, hospice care, and infusion therapy.
Ascension Health will form a joint venture with a division of Envision Healthcare to provide an array of post-acute services. The arrangement will include home care, hospice care, and infusion therapy, and under the agreement Envision’s subsidiary, Evolution Health, will be an exclusive partner to provide these services.
The new joint venture will include 5 of Ascension Health’s 23 communities and will begin at the end of this year. According to estimates, revenues should be $75-$100 million, and Ascension expects to expand into additional communities over the next 3 years.
“This agreement furthers Ascension’s focus on delivering person-centered care to individuals in a variety of settings, which is key to our efforts to manage the health of patient populations,” Anthony R. Tersigni, EdD, FACHE, president and chief executive officer (CEO) of Ascension, said in a statement. “Providing service in the home and through alternative facilities to people in need of care, including those who are poor and vulnerable, is one way we extend our ministry beyond hospital walls and reach individuals and families where and when they need us.”
The partnership will expand the footprint of Evolution Health by providing services in new markets. President and CEO William A. Sanger expects that working together with Ascension to deliver post-acute and home care services will improve both patient outcomes and satisfaction.
The Ascension Health Senior Care unit was only formed on July 30 and ranks as the second-largest not-for-profit long-term care provider in the United States. The organization oversees 5,568 senior care/senior living beds and 3 Program of All-inclusive Care for the Elderly.
“We believe there is much to be learned by working with Evolution Health in a way that ensures the most effective and efficient care across our national health ministry in support of our Mission of serving all persons,” added Robert J. Henkel, FACHE, president and CEO of Ascension Health, a direct subsidiary of Ascension.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More